Literature DB >> 17317204

Local radiofrequency ablation techniques for liver metastases of colorectal cancer.

J Joosten1, T Ruers.   

Abstract

Local ablative techniques have been used for several decades in the treatment of colorectal liver metastases and are gaining more and more interest. At this time radiofrequency ablation is the most popular local ablative technique with interesting results on local tumour control, disease free and overall survival. However, the exact place in the treatment of non-resectable colorectal liver metastases and its possible place in the treatment of resectable liver metastases has still to be defined. This article describes the feasibility, advantages and disadvantages of radiofrequency ablation, together with the results of the most cited articles, to form a critical review on the use of this technique in the treatment of colorectal liver metastases.

Entities:  

Mesh:

Year:  2007        PMID: 17317204     DOI: 10.1016/j.critrevonc.2006.12.001

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  3 in total

1.  Differentiation of benign periablational enhancement from residual tumor following radio-frequency ablation using contrast-enhanced ultrasonography in a rat subcutaneous colon cancer model.

Authors:  Hanping Wu; Ravi B Patel; Yuanyi Zheng; Luis Solorio; Tianyi M Krupka; Nicholas P Ziats; John R Haaga; Agata A Exner
Journal:  Ultrasound Med Biol       Date:  2012-01-21       Impact factor: 2.998

Review 2.  Radiofrequency ablation as a treatment tool for liver metastases of colorectal origin.

Authors:  D Hompes; W Prevoo; T Ruers
Journal:  Cancer Imaging       Date:  2011-03-24       Impact factor: 3.909

Review 3.  Irreversible electroporation in primary and metastatic hepatic malignancies: A review.

Authors:  Tianchu Lyu; Xifu Wang; Zhanliang Su; Junjie Shangguan; Chong Sun; Matteo Figini; Jian Wang; Vahid Yaghmai; Andrew C Larson; Zhuoli Zhang
Journal:  Medicine (Baltimore)       Date:  2017-04       Impact factor: 1.889

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.